Properties
What is it?
International Nonproprietary Name - Ferri(III) hydroxidum polymaltosatum Pharmacological group: Anti-anemic agents Dosage form: Solution for intravenous injection Composition: 1 ampoule (5ml) contains: Active substance: Iron (III) hydroxide-sucrose complex, equivalent to 100 mg of elemental iron. Pharmacotherapeutic group: Anti-anemic preparation/Iron (III) preparation for parenteral use Indications: In iron deficiency anemia where oral iron therapy has proven insufficient, ineffective, or unacceptable for use (intolerance to iron preparations, malabsorption, inflammatory conditions of the digestive system, ulcerative colitis) In iron deficiency anemia that developed in patients during chronic hemodialysis. In cases where erythropoietin was administered as additional therapy. The use of the ampoule is necessary only after appropriate blood tests (e.g., hemoglobin, hematocrit, ferritin level, red blood cell count) Dosage and administration: Since there is no data on the efficacy and safety of the preparation in children, it should be used only in adults. One ampoule (100 mg) 1-3 times a week. The total dose for hemodialysis patients is 1000 mg, which should be divided into 10 doses. The recommended dose can be repeated if necessary, the frequency should not exceed three times a week. The preparation should be used only intravenously (by slow injection or infusion). Slow intravenous injection is recommended, calculated as follows: undiluted 1 ml per minute. Only one ampoule should be used for one injection; any residue in the ampoule after use should be discarded. For infusion, each ampoule should be diluted immediately before use in 100 ml of 0.9% sodium chloride solution. The prepared solution is administered to patients over 15 minutes. Slow intravenous administration of the preparation reduces the risk of hypotensive crisis. The ampoule cannot be mixed with other medicinal preparations. Side effects: In patients, in rare cases, it can cause hypotension, limb cramps, nausea, vomiting, diarrhea, urticaria. In women, anaphylactic reactions rarely develop; safety measures should be taken. Contraindications: Hypersensitivity to the components of the composition; during iron overload (hemochromatosis, chronic hemolysis, disorders of iron utilization mechanisms, lead-induced anemia, sideroachrestic anemia); thalassemia; non-iron deficiency anemias (hemolytic anemia). Regular blood transfusions. First trimester of pregnancy. Severe form of liver cirrhosis or hepatitis. Pregnancy and lactation: According to its effect on the fetus, it belongs to category B according to FDA. The preparation should be used only in cases of extreme necessity.